

Client: Example Client ABC123

123 Test Drive

Salt Lake City, UT 84108

Physician: Doctor, Example

UNITED STATES

Patient: Patient, Example

DOB 1/28/1991

Sex: Male

01234567890ABCD, 012345 **Patient Identifiers:**

Visit Number (FIN): 01234567890ABCD **Collection Date:** 01/01/2017 12:34

Lurasidone Quantitative, Serum or Plasma

ARUP test code 2013018

Lurasidone Quantitative, Serum/Plasma

28 ng/mL

Serum

Reporting Limit: 2.5 ng/mL

Synonym(s): Latuda(R) Following single dose administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 54 and 64 ng/mL, respectively. Following steady-state administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 48 and 79 ng/mL, respectively.

Peak serum concentrations and absorption occur in approximately 1 to 3 hours. Steady-state concentrations are reached within 7 days of

initiation of therapy. The elimination half-life is approximately 18 hours.
The white blood cell (WBC) count should be monitored periodically, because agranulocytosis, leukopenia, and neutropenia have been reported during clinical trials.

Analysis by High Performance Liquid Chromatography/

Tandem Mass Spectrometry (LC-MS/MS)
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug

Administration. Testing performed at NMS Labs, Inc. 200 welsh Road Horsham, PA 19044-2208 CLIA 39D0197898

| VERIFIED/REPORTED DATES | | | | |
|---------------------------------------|---------------|----------------------|----------------------|----------------------|
| Procedure | Accession | Collected | Received | Verified/Reported |
| Lurasidone Quantitative, Serum/Plasma | 22-113-400316 | 4/21/2022 8:10:00 AM | 4/25/2022 1:56:12 PM | 4/27/2022 3:40:00 PM |

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical